Phase 2 N=23 sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Skin Kaposi Sarcoma
Primary: Proportion of Participants Experiencing Clinical Response — 56.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Sarcoma
Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion
N/A N=6 Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Sarcoma
Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants
Phase 2 N=28 Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Kaposi Sarcoma · Sarcoma, Kaposi
Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants
N/A N=29 Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
Kaposi's Sarcoma
Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius
Phase 2 N=26 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Human Immunodeficiency Virus 1 Positive · Skin Kaposi Sarcoma
Primary: Overall Response Rate — 0.577 proportion of participants
Phase 2 N=19 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
Kaposi's Sarcoma · HIV Infections · HIV Seronegativity
Primary: Response Rate — 31 Percentage of participants
Phase 2 N=16 Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Sarcoma, Kaposi
Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants
Phase 2 N=3 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
Phase 2 N=36 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Recurrent Kaposi Sarcoma · Skin Kaposi Sarcoma
Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…
Phase 2 N=13 Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Kaposi's Sarcoma
Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants
N/A N=10 Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
AIDS-Related Kaposi Sarcoma · Human Immunodeficiency Virus 1 Positive
Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
Phase 1 N=15 An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Kaposi Sarcoma · HIV Infections
Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals
Phase 2 N=40 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
Phase 2 N=15 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Kaposi's Sarcoma · HIV Positive · AIDS
Primary: Objective Response Rate — 0; 7; 6 Participants
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=8 Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Castleman Disease · Multicentric Castleman Disease · Giant Lymph Node Hyperplasia
Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants
Phase 2 N=5 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Kaposi's Sarcoma
Primary: Localization — 5 participants
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=58 A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients
Phase 2 N=53 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Phase 2 N=51 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Phase 2 N=20 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants